Mariana Lavrador

Dr. Mariana Lavrador


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2021 in Endocrinology, Diabetes & Metabolism Case Reports
Verified
Journal Article
Open access
PDF file
MLMariana Lavrador
Mariana Lavrador
ALAdriana De Sousa Lages
Adriana De Sousa Lages
LBLuísa Barros
Luísa Barros
IPIsabel Paiva
Isabel Paiva
Summary: Congenital adrenal hyperplasia (CAH) is a group of autosomal recessive disorders related to enzyme deficiencies in the adrenal steroidogenesis pathway leading to impaired corticosteroid biosynthesis. Depending on the extension of enzyme defect, there may be variable severities of CAH – classic and non-classic. We report the case of a 37-year-old male patient with a previously unknown diagnosis of classic CAH referred to Endocrinology evaluation due to class III obesity and insulin resistance. A high diagnostic suspicion was raised at the first Endocrinology consultation after careful past medical history analysis especially related to the presence of bilateral adrenal myelolipomas and primary infertility. A genetic test confirmed the presence of a variant of the CYP21A2 in homozygous with an enzymatic activity of 0–1%, corresponding to a classic and severe CAH form. Our case represents an unusually late definitive diagnose of classic CAH since the definition was established only during adulthood in the fourth decade of life. The missing diagnosis of classic 21 hydroxylase deficiency during infancy led to important morbidity, with a high impact on patients’ quality of life. Learning points: Congenital adrenal hyperplasia (CAH) refers to a group of autosomal recessive enzyme disorders responsible for an impaired cortical adrenal hormonal synthesis. CAH may be divided into two major forms: classic and non-classic CAH. If untreated, CAH may be fatal or may be responsible for important multi-organ long-term consequences that can be undervalued during adulthood. Adrenal myelolipomas are associated with chronic exposure to high ACTH levels and continuous androgen hyperstimulation typically found in undertreated CAH patients. Testicular adrenal rest tumours (TART) and primary infertility can be the first manifestation of the disease during adulthood.

Verified
Journal Article
Open access
PDF file
LFLúcia Fadiga
Lúcia Fadiga
MLMariana Lavrador
Mariana Lavrador
NVNuno Vicente
Nuno Vicente
LBLuísa Barros
Luísa Barros
IGIsabel Goncalves
Isabel Goncalves
MLManuel Lemos
Manuel Lemos
Congenital hypogonadotropic hypogonadism (CHH) is a rare reproductive endocrine disorder characterized by complete or partial failure of pubertal development and infertility due to deficiency of the gonadotropin-releasing hormone (GnRH). CHH has a significant clinical heterogeneity and can be caused by mutations in over 30 genes. The aim of this study was to investigate the genetic defect in two siblings with CHH. A woman with CHH associated with anosmia and her brother with normosmic CHH were investigated by whole exome sequencing. The genetic studies revealed a novel heterozygous missense mutation in the Fibroblast Growth Factor Receptor 1 (FGFR1) gene (NM_023110.3: c.242T>C, p.Ile81Thr) in the affected siblings and in their unaffected father. The mutation affected a conserved amino acid within the first Ig-like domain (D1) of the protein, was predicted to be pathogenic by structure and sequence-based prediction methods, and was absent in ethnically matched controls. These were consistent with a critical role for the identified missense mutation in the activity of the FGFR1 protein. In conclusion, our identification of a novel missense mutation of the FGFR1 gene associated with a variable expression and incomplete penetrance of CHH extends the known mutational spectrum of this gene and may contribute to the understanding of the pathogenesis of CHH.

2 November 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
AMAlice Monsanto
Alice Monsanto
BJBárbara Almeida Jesus
Bárbara Almeida Jesus
ADAdriana Duarte
Adriana Duarte
MLMariana Lavrador
Mariana Lavrador
MVMara Ventura
Mara Ventura
LGLeonor Gomes
Leonor Gomes
Background: Acromegaly is most commonly caused by a growth hormone (GH)-secreting pituitary neuroendocrine tumour (PitNET). Plurihormonal PIT1-lineage PitNETs are uncommon, and combined GH and thyroid-stimulating hormone (TSH) secretion poses distinctive diagnostic and therapeutic challenges. We report a mixed GH/TSH-secreting PIT1-lineage PitNET in which the biochemical response to preoperative lanreotide supported the clinical suspicion of a functionally relevant thyrotroph component before targeted pathological reassessment. Case Presentation: A 39-year-old woman presented with a two-year history of progressive acral enlargement, headaches, hyperhidrosis, snoring, and voice deepening. Biochemical evaluation showed IGF-1 1128 ng/mL (reference range 93.1–281), GH 61 µg/L, TSH 1.5 µIU/mL (0.35–4.94), FT4 1.66 ng/dL (0.7–1.5), and FT3 7.0 pg/mL (1.8–4.2). Pituitary MRI demonstrated a 15 × 14 × 10.5 mm macroadenoma. Lanreotide 120 mg every four weeks reduced IGF-1 to 846 ng/mL and GH to 14 µg/L while normalizing FT4 (1.04 ng/dL) and FT3 (3.9 pg/mL), reinforcing the suspicion of mixed GH/TSH secretion. Transsphenoidal surgery was performed in October 2024. The tumour was initially classified as a densely granulated somatotroph PitNET; prompted by the preoperative biochemical phenotype, additional β-TSH immunostaining demonstrated positivity in numerous tumour cells, leading to reclassification as a mature plurihormonal PIT1-lineage PitNET (Ki-67 approximately 1%). Postoperative biochemical remission was not achieved, and MRI demonstrated a 7 mm residual lesion. Lanreotide was resumed, with the sustained control of the thyrotroph component but persistent GH/IGF-1 excess. Because residual disease persisted with slight cavernous sinus extension, Gamma Knife radiosurgery was performed in July 2026. Conclusions: Mixed GH/TSH-secreting PIT1-lineage PitNETs may be overlooked when TSH is inappropriately normal rather than frankly elevated. This case illustrates the value of integrating biochemical findings, treatment response, and targeted histopathological reassessment. Persistent disease despite surgery and somatostatin receptor ligand therapy further highlights the frequent need for multimodal, long-term management.

10 September 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
AMAlice Monsanto
Alice Monsanto
BJBárbara Almeida Jesus
Bárbara Almeida Jesus
ADAdriana Duarte
Adriana Duarte
MLMariana Lavrador
Mariana Lavrador
MVMara Ventura
Mara Ventura
LGLeonor Gomes
Leonor Gomes
Background: Acromegaly is most commonly caused by a growth hormone (GH)-secreting pituitary neuroendocrine tumor (PitNET). Plurihormonal PIT1-lineage PitNETs are uncommon, and combined GH and thyroid-stimulating hormone (TSH) secretion poses distinctive diagnostic and therapeutic challenges. We report a mixed GH/TSH-secreting PIT1-lineage PitNET in which biochemical response to preoperative lanreotide supported the clinical suspicion of co-secretion before histopathological confirmation. Case Presentation: A 39-year-old woman presented with a two-year history of progressive acral enlargement, headaches, hyperhidrosis, snoring, and voice deepening. Biochemical evaluation showed IGF-1 1128 ng/mL (reference range 93.1–281), GH 61 µg/L, TSH 1.5 µIU/mL (0.35–4.94), FT4 1.66 ng/dL (0.7–1.5), and FT3 7.0 pg/mL (1.8–4.2). Pituitary MRI demonstrated a 15 × 14 × 10.5 mm macroadenoma. Lanreotide 120 mg every four weeks reduced IGF-1 to 846 ng/mL and GH to 14 µg/L, while normalizing FT4 (1.04 ng/dL) and FT3 (3.9 pg/mL), reinforcing suspicion of mixed GH/TSH secretion. Transsphenoidal surgery was performed in October 2024. The tumor was initially classified as a densely granulated somatotroph PitNET; prompted by the preoperative biochemical phenotype, additional β-TSH immunostaining demonstrated positivity in numerous tumor cells, leading to reclassification as a mature plurihormonal PIT1-lineage PitNET (Ki-67 approximately 1%). Postoperative biochemical remission was not achieved, and MRI demonstrated a 7 mm residual lesion. Lanreotide was resumed, with sustained control of the thyrotroph component but persistent GH/IGF-1 excess. Because residual disease persisted with slight cavernous sinus extension, Gamma Knife radiosurgery was performed in July 2026. Conclusions: Mixed GH/TSH-secreting PIT1-lineage PitNETs may be overlooked when TSH is inappropriately normal rather than frankly elevated. This case illustrates the value of integrating biochemical findings, treatment response, and targeted histopathological reassessment. Persistent disease despite surgery and somatostatin receptor ligand therapy further highlights the frequent need for multimodal, long-term management.